Patents by Inventor Michael Imboden
Michael Imboden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11434259Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika, dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.Type: GrantFiled: January 25, 2017Date of Patent: September 6, 2022Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Publication number: 20200402615Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.Type: ApplicationFiled: August 6, 2020Publication date: December 24, 2020Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Patent number: 10755801Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.Type: GrantFiled: July 10, 2015Date of Patent: August 25, 2020Assignee: IOGENETICS, LLCInventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Publication number: 20190031722Abstract: The present invention relates to vaccine compositions and therapeutic interventions for treating and preventing infections and diseases caused by flaviviruses, including Zika dengue, and Usutu virus. It also relates to compositions and methods for diagnosis and differential diagnosis of flaviviruses and co-endemic pathogens.Type: ApplicationFiled: January 25, 2017Publication date: January 31, 2019Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Publication number: 20170161430Abstract: The present invention provides methods and systems for identifying and classifying epitopes and use of that information to analyze proteins and peptides within proteins, especially potential epitopes, and to use the information to design synthetic peptides and proteins, analyze biopharmaceutical proteins, and diagnose autoimmune conditions. Peptides which are bound in MHC grooves comprise two sets of amino acids: those that face inwards into the groove and determine the binding affinity to the MHC molecule (the groove exposed motifs or GEM) and those which do not interact with the groove but rather are on the obverse side exposed outwardly to the T-cells (the T-cell exposed Motifs or TCEM). The present invention utilizes information related to the identity and physiochemical characteristics of the GEM and TCEM.Type: ApplicationFiled: July 10, 2015Publication date: June 8, 2017Inventors: Robert D. Bremel, Jane Homan, Michael Imboden
-
Publication number: 20150284452Abstract: The present invention relates antimicrobial compositions, and in particular to antigen binding proteins comprising one or more domains that provide antimicrobial activity.Type: ApplicationFiled: November 13, 2013Publication date: October 8, 2015Applicant: IOGENETICS, LLCInventors: Robert Duane Bremel, Jane Homan, Michael Imboden, Brendan Keough
-
Patent number: 8703134Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: February 6, 2013Date of Patent: April 22, 2014Assignees: ioGenetics, LLC, Arizona Board of Regents on Behalf of the University of ArizonaInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Publication number: 20130230516Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: February 6, 2013Publication date: September 5, 2013Applicants: Arizona Board of Regents on behalf of the University of Arizona, ioGenetics, LLCInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan, Robert D. Bremel
-
Patent number: 8394379Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: GrantFiled: January 13, 2010Date of Patent: March 12, 2013Assignee: ioGenetics, LLCInventors: Michael Imboden, Michael Warren Riggs, Deborah A. Schaefer, Jane Homan
-
Patent number: 8222188Abstract: The present invention relates to the production of antibody libraries. In particular, the present invention relates to the use of integrating retroviral vectors to generate libraries comprising a plurality of combinations of antibody light chains and heavy chains. The present invention thus provides improved methods of generating and screening antibody libraries comprising large numbers of unique antibodies.Type: GrantFiled: June 29, 2009Date of Patent: July 17, 2012Assignee: Catalent Pharma Solutions, LLCInventors: Robert D. Bremel, Kurt Eakle, Michael Imboden
-
Publication number: 20100183611Abstract: The present invention relates to fusion proteins comprising a microorganism targeting molecule (e.g., immunoglobulin) and a biocide. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in diverse fields.Type: ApplicationFiled: January 13, 2010Publication date: July 22, 2010Applicants: IOGENETICS, LLC., ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONAInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer, Jane Homan
-
Publication number: 20100111976Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: September 24, 2009Publication date: May 6, 2010Applicant: IOGENETICS, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20100034824Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzyme) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: August 5, 2009Publication date: February 11, 2010Applicants: IOGENETICS, LLC, THE ARIZONA BOARD OF REGENTSInventors: Michael Imboden, Michael Riggs, Deborah A. Schaefer
-
Publication number: 20100009869Abstract: The present invention relates to the production of antibody libraries. In particular, the present invention relates to the use of integrating retroviral vectors to generate libraries comprising a plurality of combinations of antibody light chains and heavy chains. The present invention thus provides improved methods of generating and screening antibody libraries comprising large numbers of unique antibodies.Type: ApplicationFiled: June 29, 2009Publication date: January 14, 2010Inventors: Robert D. Bremel, Kurt Eakle, Michael Imboden
-
Patent number: 7566447Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: GrantFiled: October 20, 2005Date of Patent: July 28, 2009Assignees: Iogenetics, LLC, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Jane Homan, Michael Imboden, Michael Riggs, Stephane Carryn, Deborah A. Schaefer
-
Publication number: 20090098121Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: April 16, 2009Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080274095Abstract: The present invention relates to the use of biocide (e.g., bactericidal enzyme) to target pathogens. In particular, the present invention provides biocides for use in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., water purification).Type: ApplicationFiled: October 19, 2005Publication date: November 6, 2008Inventors: Jane Homan, Michael Imboden, Michael W. Riggs, Stephane Carryn
-
Publication number: 20080267943Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Publication number: 20080269122Abstract: The present invention relates to retroviral constructs that encode novel monoclonal antibodies, novel fusion proteins, and chimeric monoclonal antibodies and to methods of using and producing the same. In particular, the present invention relates to methods of producing a fusion protein comprising a microorganism targeting molecule (e.g., immunoglobulin or innate immune system receptor molecule) and a biocide (e.g., bactericidal enzymes) in transgenic animals (e.g., bovines) and in cell cultures. The present invention also relates to therapeutic and prophylactic methods of using a fusion protein comprising a microorganism targeting molecule and a biocide in health care (e.g., human and veterinary), agriculture (e.g., animal and plant production), and food processing (e.g., beef carcass processing).Type: ApplicationFiled: October 19, 2007Publication date: October 30, 2008Applicant: ioGenetics, LLCInventors: Michael Imboden, Jane Homan, Robert D. Bremel
-
Patent number: 7384738Abstract: The present invention relates to the expression and screening of genomic DNA sequences encoding uncharacterized genes and proteins. The present invention provides systems utilizing unique features of retroviral replication to analyze uncharacterized genes derived from genomic DNA samples. In preferred embodiments, a segment of genomic DNA is inserted between 5? and 3? viral long terminal repeats (LTRs) in a vector (e.g., a plasmid, cosmid, or artificial chromosome vector). The resulting vector (or library of vectors containing a plurality of independent genomic sequences) is then introduced into a retroviral packaging cell. The resulting provirus or proteins expression from the provirus are then analyzed.Type: GrantFiled: March 26, 2003Date of Patent: June 10, 2008Inventors: Robert D. Bremel, Gregory T. Bleck, Michael Imboden, Kurt Eakle